References
- Blaser J, Stone BB, Groner MC, Zinner SH. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob Agents Chemother 1987; 31: 1054–60.
- Drusano GL. Role of pharmacokinetics in the outcome of infections. Antimicrob Agents Chemother 1988; 32: 289–97.
- Dudley MN, Mandler HG, Gilbert D, Ericson J, Mayer KH, Zinner SH. Pharmocokinetics and pharmacodynamics of intravenous ciprofloxacin. Am J Med 1987; 82: 363–8.
- Gerber AU, Craig WA, Brugger HP, Feller C, Vastolla AP, Brandel J. Impact of dosing intervals on activity of gentamicin and ticarcillin against Pseudomonas aeruginosa in granulocytopenic mice. J Infect Dis 1983; 147: 910–7.
- Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimum inhibitory concentration. J Infect Dis 1987; 155: 93–9.
- Moore RD, Smith CR, Lietman PS. Association of aminoglycoside plasma levels with therapeutic outcome in Gram-negative pneumonia. Am J Med 1984; 77: 657–62.
- Schentag JJ, Smith IL, Swanson DJ, et al. Role for dual individualisation with cefmenoxime. Am J Med 1984; 77, Suppl. 6a: 43–50.
- Drusano GL, Forrest A, Plaisance KI, Wade JC. A prospective evaluation of optimal sampling theory in the determination of the steady-state pharmacokinetics of piperacillin in febrile neutropenic cancer patients. Clin Pharmacol Therapeut 1989; 45: 635–41.
- Peloquin CA, Cumbo TJ, Nix DE, Sands MF, Schentag JJ. Evaluation of intravenous ciprofloxacin in patients with lower respiratory tract infections: impact of plasma concentrations, organism, MIC and clinical condition on bacterial eradication. Arch Intern Med 1989; 149: 2269–73.
- Drusano GL, Forrest A, Snyder MJ, Reed MD, Blumer JL. An evaluation of optimal sampling stratergy and adaptive study design. Clin Pharmacol Therapeut 1988; 44: 232–8.
- Leggett JE, Ebert S, Fantin B, Craig WA. Comparative dose-effect relations at several dosing intervals for b-lactam, aminoglycoside and quinolone antibiotics against Gram-negative bacilli in murine thigh-infection and pneumonitis models. Scand J Infect Dis 1991; 74: 179–84.
- Yuen GJ, Drusano GL, Forrest A, Plaisance KI, Kaplan ES. Prospective use of optimal sampling theory. Clin Pharmacol Therapeut 1990; 46: 451–7.
- Sheiner LB, Rosenberg B, Marathe VV. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J Pharmacokinet Biopharm 1977; 5: 445–79.
- Gitterman SR, Drusano GL, Egorin MJ, Standiford HC, and the Veterans Administration Clinical Trials Group. Population pharmacokinetics of zidovudine. Clin Pharmacol Therapeut 1990; 48: 161–7.
- Schumitzky A. Non-parametric EM algorithms for estimating prior distributions. Appl Mathemat Comput 1991; 45: 143–57.
- Preston SL, Drusano GL. Non-parametric expectation maximisation (NPEM2) modelling of ganciclovir. J Clin Pharmacol 1996; 36: 301–10.
- Drusano GL, Johnson DE, Rosen M, Standiford HC. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob Agents Chemother 1993; 37: 483–90.
- Preston SA, Drusano GL, Berman AL, et al. Pharmacodynamics of levofloxacin: A new paradigm for early clinical trials. JAMA 1998; 279: 125–9.
- Hooper DC, Wolfson JS, Ng EY, Swartz MN. Mechanism of action and resistance to ciprofloxacin. Am J Med 1987; 82, Suppl. 4A: 12–20.